Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-038616
Filing Date
2025-04-24
Accepted
2025-04-24 16:02:51
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10475
2 EXHIBIT I tm2513105d1_ex-1.htm EX-99.1 5608
  Complete submission text file 0001104659-25-038616.txt   17890
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-85205 | Film No.: 25867182
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022
Business Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022 (212) 841-4100
INTEGRATED CORE STRATEGIES (US) LLC (Filed by) CIK: 0001319244 (see all company filings)

EIN.: 980330397 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A